key: cord-1000542-f7rlespe
authors: Hamamoto, Yoshiyuki
title: The Covid‐19 world—Are we there yet?
date: 2021-05-31
journal: J Diabetes Investig
DOI: 10.1111/jdi.13605
sha: 5cfe047cef75f23b5a53acf2b6b419e88e0ac25d
doc_id: 1000542
cord_uid: f7rlespe

The emergence of variants of respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and their rapid spread over the world casts a shadow over the potential victory for this human tragedy enabled by the novel and highly effective vaccines. Coronavirus disease 2019 (COVID‐19) cases surpassed 100 million on January 27, 2021 according to the Center for Systems Science and Engineering at Johns Hopkins University, which indicates that more than one of 80 humans on earth has already been infected. Some of the variants, especially the U.K. coronavirus variant (B.1.1.7), the South Africa variant (B.1.351), and the recently identified India variant (B.1.617) are more infectious and deadlier compared to SARS‐CoV‐2 before their appearance. The currently known major variants are characterized by mutations in the receptor‐binding domain of their spike‐protein (e.g., N501Y, E484K, and K417T/N); the India variant has two characteristic mutations of E484Q and L452R that may impact vaccine efficacy. COVID‐19 is distinguished from other infectious diseases by its two‐faced clinical presentation: it is sometimes almost asymptomatic despite its transmission potential or it may present with pneumonia that can lead to rapid disease progression and fatal outcome.

protein (e.g., N501Y, E484K, and K417T/N); the India variant has two characteristic mutations of E484Q and L452R that may impact vaccine efficacy. COVID-19 is distinguished from other infectious diseases by its two-faced clinical presentation: it is sometimes almost asymptomatic despite its transmission potential or it may present with pneumonia that can lead to rapid disease progression and fatal outcome.

As diabetes and obesity are well known risk factors for severity and mortality of COVID-19, maintaining good glycemic control and appropriate body weight during the pandemic has become ever more important to patients and their physicians. While healthy eating and adequate physical activity are essential for patients with diabetes to maintain their glycemic control and body weight at all times, it has been reported that containment measures for COVID-19 negatively affect both nutrition and exercise of patients with diabetes. We have reported that even under the mild containment measure imposed in Japan, patients with diabetes exhibited lifestyles altered toward a more sedentary mode, which caused deterioration of glycemic control and weight gain, more seriously in the elderly population 1 . Even slightly reduced regular daily activities in elderly patients can eventually lead to loss of skeletal muscle mass, and could pose a serious social health issue in the future. Thus, maintaining a physical activity level is especially

important under a stay-at-home order to maintain muscle mass in the elderly ( Figure. It is not known whether the vaccines are similarly effective among patients having underlying diseases, especially those associated with an immunocompromised state such as diabetes, cancer, and immune disease. We found that in elderly Japanese patients with diabetes,

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved Early diagnosis and initiation of treatment as soon as possible is key to overcome COVID-19 infection. Recently developed monoclonal antibodies for SARS-CoV-2 (they are to be used as combination therapy such as bamlanivimab and etesevimab or Casirivimab and imdevimab) are being used in treatment of mild to moderate COVID-19 patients not hospitalized but at high risk of disease progression and/or hospitalization, such as patients with diabetes, chronic kidney disease, and severe obesity, but they are available only in limited countries and their application is restricted due to their administration by infusion. In this respect, development of molnupiravir, an orally administered bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine, is expected and is currently under phase 3 clinical trial for outpatients with COVID-19.

Glycemic control before and during COVID-19 infection in addition to the drugs used for hypertension and diabetes treatment are also significant factors affecting severity and mortality of the disease. Glycemic control is an essential strategy for COVID-19 treatment; poor glycemic control results in impaired immune defense and abnormal immune response, which in COVID-19 infection can lead to severe pneumonia and acute respiratory distress syndrome 7 . It is also thought that impairment of vascular endothelial cells due to poor glycemic control is involved in the poor outcome of patients with diabetes in the progression of COVID-19 infection. There is both expectation and concern regarding the glucose-lowering drugs in relation to COVID-19 infection. As suggested in the Sitagliptin Treatment in Diabetic COVID-19 Positive Patients (SIDIACO-RETRÒ) study reported by Italian researchers, DPP-4 inhibitors may reduce mortality in patients with COVID-19 infection 8 . The effect was confirmed by meta-analysis study 9 . Metformin is also expected to have a beneficial effect in terms of reducing mortality due to COVID-19 infection despite the concern for increased lactic acidosis by a hazard ratio of 4.66 (95% confidence interval: 1.45-14.99) as summarized in the article by Lui DTW et al. 10 . The relation between glucose-lowering drugs and the severity and mortality of COVID-19 infection in Accepted Article diabetes patients is still largely unknown and warrants further investigation. Again, the key to successful treatment of severe COVID-19 infection is early diagnosis and prompt initiation of treatment. In this respect, patients with diabetes should have better access to medical services than they presently do. Moreover, if herd immunity and effective treatment are not established, those who are at highest risk from infection of COVID-19 would have to continue in voluntary lock-down indefinitely. The efficacies of the vaccines and treatments in certain groups such as patients with underlying diseases including diabetes, require verification.

Y Hamamoto received speaker fees from Novo Nordisk Pharma Ltd and received a research grant from Sumitomo-Dainippon Pharma Co., Ltd. and Nippon Boehringer Ingelheim.

Lifestyle changes as a result of COVID-19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Efficacy and safety of live varicella vaccine in diabetes patients: a Randomized, Double-blind, Placebo-controlled, Clinical Trial. Accepted Article This article is protected by copyright

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Does glycemic control rescue type 2 diabetes patients from COVID-19-related deaths?

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) -A systematic review, metaanalysis, and meta-regression

Is metformin a miracle or a menace in COVID-19 patients with type 2